Evidence map›Paper›PMID 33069225›Full record

ArticleBMC cancer2020

Inducing multiple antibodies to treat squamous cell esophageal carcinoma.

Isamu Hoshino, Yoshihiro Nabeya, Nobuhiro Takiguchi, Hisashi Gunji, Fumitaka Ishige, Yosuke Iwatate, Akiko Kuwajima, Fumiaki Shiratori, Rei Okada, Hideaki Shimada

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Isamu HoshinoDivision of Gastroenterological Surgery, Chiba Cancer Center, 666-2 Nitonacho, Chuo-ku, Chiba, 260-8717, Japan. ihoshino@chiba-cc.jp.ORCID http://orcid.org/0000-0002-8156-1752
Yoshihiro NabeyaDivision of Gastroenterological Surgery, Chiba Cancer Center, 666-2 Nitonacho, Chuo-ku, Chiba, 260-8717, Japan.
Nobuhiro TakiguchiDivision of Gastroenterological Surgery, Chiba Cancer Center, 666-2 Nitonacho, Chuo-ku, Chiba, 260-8717, Japan.
Hisashi GunjiDivision of Gastroenterological Surgery, Chiba Cancer Center, 666-2 Nitonacho, Chuo-ku, Chiba, 260-8717, Japan.
Fumitaka IshigeDepartment of Hepatobiliary and Pancreatic Surgery, Chiba Cancer Center, 666-2 Nitonacho, Chuo-ku, Chiba, Japan.
Yosuke IwatateDepartment of Hepatobiliary and Pancreatic Surgery, Chiba Cancer Center, 666-2 Nitonacho, Chuo-ku, Chiba, Japan.
Akiko KuwajimaMedical & Biological Laboratories Co., Ltd, 4-5-3 Sakae, Naka-ku, Nagoya, 460-0008, Japan.
Fumiaki ShiratoriDivision of Gastroenterological Surgery, Chiba Cancer Center, 666-2 Nitonacho, Chuo-ku, Chiba, 260-8717, Japan.
Rei OkadaDepartment of Gastroenterological Surgery and Clinical Oncology, Graduate School of Medicine, Toho University, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan.
Hideaki ShimadaDepartment of Gastroenterological Surgery and Clinical Oncology, Graduate School of Medicine, Toho University, 6-11-1 Omori-Nishi, Ota-ku, Tokyo, 143-8541, Japan.
Chiba Cancer Center · JPToho University · JPMedical & Biological Laboratories (Japan) · JP

Funding

JSPS KAKENHI JP15K10117JSPS KAKENHI JP16K10520
6 · The paper itself

Abstract

backgroundThe positive response and the clinical usefulness of 14 serum antibodies in patients with esophageal squamous cell carcinoma (ESCC) were examined in this study. The Cancer Genome Atlas (TCGA) was used to investigate the frequency of gene expressions, mutations, and amplification of these 14 antigens and also the possible effects of antibody induction.

methodsBlood serum derived from 85 patients with ESCC was collected and analyzed for the 14 antibodies using ELISA. The prognosis between positive and negative antibodies were then compared. The antibody panel included LGALS1, HCA25a, HCC-22-5, and HSP70.

resultsPatient serum was positive for all antibodies, except VEGF, with the positive rates ranging from 1.18 to 10.59%. Positive rates for LGALS1, HCA25a, HCC-22-5, and HSP70 were > 10%. TCGA data revealed that all antigen-related genes had little or no mutation or amplification, and hence an increase in gene expression affected antibody induction. The positive results from the panel accounted for the positive rate comparable to the combination of CEA and SCC. No significant association was observed between the presence of antibodies and disease prognosis.

conclusionsThe detection rates of LGALS1, HCA25a, HCC-22-5, and HSP70 were 10% higher in patients with ESCC. Gene overexpression may be involved in such antibody production. These four antibodies were applied as a panel in comparison with conventional tumor markers. Moreover, it was confirmed that the combination of this panel and the conventional tumor markers significantly improved the positive rate.

Indexed as

AgedAged, 80 and overAntigens, NeoplasmAutoantibodiesEsophageal NeoplasmsEsophageal Squamous Cell CarcinomaFemaleGalectin 1Gene Expression Regulation, NeoplasticHSP70 Heat-Shock ProteinsHumansMaleMiddle AgedPrognosisAntigens, NeoplasmAutoantibodiesGalectin 1HCC-22-5 antigen, humanHSP70 Heat-Shock ProteinsLGALS1 protein, humanAutoantibodyEsophageal squamous cell carcinomaTCGA

Identifiers

PMID33069225
PMCPMC7568359
OpenAlexW3092657875

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.